Acts as a transcriptional repressor. Corepressor for REST. Interacts with MXI1 to repress MYC responsive genes and antagonize MYC oncogenic activities. Also interacts with MXD1-MAX heterodimers to repress transcription by tethering SIN3A to DNA. Acts cooperatively with OGT to repress transcription in parallel with histone deacetylation. Interacts with BAZ2A, MXD3, MXD4, MBD2, NCOR1, NR4A2, REST, RLIM, SAP30, SETDB1 and SMYD2. Interacts with PHF12 in a complex composed of HDAC1, PHF12 and SAP30. Interacts with ARID4B, BRMS1L, DACH1, HCFC1, HDAC1, HDAC2, MXI1, SAP30L, SAP130, SFPQ, SUDS3 and TOPORS. Interacts with TET1; the interaction recruits SIN3A to gene promoters. Interacts with OGT (via TPRs 1-6); the interaction mediates transcriptional repression in parallel with histone deacetylase. Note: This description may include information from UniProtKB.
Protein type: Transcription, coactivator/corepressor; Nucleolus; Nuclear receptor co-regulator
Molecular Function: protein binding; protein deacetylase activity; protein complex binding; chromatin binding; histone deacetylase activity; transcription factor activity
Biological Process: positive regulation of chromatin silencing; transcription, DNA-dependent; in utero embryonic development; rhythmic process; histone deacetylation; cellular lipid metabolic process; negative regulation of transcription from RNA polymerase II promoter; response to organic nitrogen; regulation of gene expression, epigenetic; protein amino acid deacetylation; negative regulation of gene expression, epigenetic; response to methylglyoxal; negative regulation of circadian rhythm; gene expression; hemopoietic progenitor cell differentiation; positive regulation of transcription from RNA polymerase II promoter; positive regulation of defense response to virus by host; negative regulation of transcription, DNA-dependent; blood coagulation; regulation of transcription from RNA polymerase II promoter in response to oxidative stress; DNA replication; activation of innate immune response; negative regulation of apoptosis; aging
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.